Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invasion/migration and a shift of immune-inflammatory microenvironment.

Sano M, Ijichi H, Takahashi R, Miyabayashi K, Fujiwara H, Yamada T, Kato H, Nakatsuka T, Tanaka Y, Tateishi K, Morishita Y, Moses HL, Isayama H, Koike K.

Oncogenesis. 2019 Jan 18;8(2):8. doi: 10.1038/s41389-018-0117-8.

2.

Effect of home enteral nutrition after pancreaticoduodenectomy.

Ito D, Arita J, Yamamoto M, Akamatsu N, Kaneko J, Ijichi H, Kubota N, Sakamoto Y, Kokudo N, Hasegawa K.

Nutrition. 2019 Apr;60:206-211. doi: 10.1016/j.nut.2018.10.007. Epub 2018 Oct 10.

PMID:
30616102
3.

A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.

Saito K, Isayama H, Nakai Y, Takahara N, Ishigaki K, Takeda T, Hakuta R, Saito T, Uchino R, Kishikawa T, Hamada T, Mizuno S, Sasaki T, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.

Invest New Drugs. 2019 Apr;37(2):338-344. doi: 10.1007/s10637-018-0691-9. Epub 2018 Nov 9.

PMID:
30411217
4.

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.

Fujiwara H, Tateishi K, Kato H, Nakatsuka T, Yamamoto K, Tanaka Y, Ijichi H, Takahara N, Mizuno S, Kogure H, Matsubara S, Nakai Y, Koike K.

Cancer Sci. 2018 Nov;109(11):3602-3610. doi: 10.1111/cas.13784. Epub 2018 Sep 17.

5.

CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.

Tokunaga E, Fujita A, Takizawa K, Baba K, Akiyoshi S, Nakamura Y, Ijichi H, Masuda T, Koga C, Tajiri W, Ohno S, Taguchi K, Ishida M.

Breast Cancer. 2019 Jan;26(1):47-57. doi: 10.1007/s12282-018-0888-y. Epub 2018 Jul 3.

6.

Adhesive Interactions between Mononuclear Phagocytes and Intestinal Epithelium Perturb Normal Epithelial Differentiation and Serve as a Therapeutic Target in Inflammatory Bowel Disease.

Ihara S, Hirata Y, Hikiba Y, Yamashita A, Tsuboi M, Hata M, Konishi M, Suzuki N, Sakitani K, Kinoshita H, Hayakawa Y, Nakagawa H, Ijichi H, Tateishi K, Koike K.

J Crohns Colitis. 2018 Nov 9;12(10):1219-1231. doi: 10.1093/ecco-jcc/jjy088.

PMID:
29917067
7.

A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer.

Saito K, Isayama H, Sakamoto Y, Nakai Y, Ishigaki K, Tanaka M, Watadani T, Arita J, Takahara N, Mizuno S, Kogure H, Ijichi H, Tateishi K, Tada M, Hasegawa K, Fukayama M, Kokudo N, Koike K.

Med Oncol. 2018 May 30;35(7):100. doi: 10.1007/s12032-018-1158-8.

PMID:
29846849
8.

Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice.

Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, Sue S, Sugimori M, Suzuki N, Sakitani K, Ijichi H, Mori R, Endo I, Maeda S.

Sci Rep. 2018 Apr 18;8(1):6150. doi: 10.1038/s41598-018-24375-2.

9.

Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.

Koi Y, Koga C, Akiyoshi S, Masuda T, Ijichi H, Nakamura Y, Ishida M, Ohno S, Tokunaga E.

Anticancer Res. 2018 Mar;38(3):1579-1584.

PMID:
29491088
10.

Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.

Nakatsuka T, Tateishi K, Kudo Y, Yamamoto K, Nakagawa H, Fujiwara H, Takahashi R, Miyabayashi K, Asaoka Y, Tanaka Y, Ijichi H, Hirata Y, Otsuka M, Kato M, Sakai J, Tachibana M, Aburatani H, Shinkai Y, Koike K.

Oncogene. 2017 Nov 9;36(45):6262-6271. doi: 10.1038/onc.2017.222. Epub 2017 Jul 10.

PMID:
28692045
11.

Prevalence of Pancreatic Cystic Lesions Is Associated With Diabetes Mellitus and Obesity: An Analysis of 5296 Individuals Who Underwent a Preventive Medical Examination.

Mizuno S, Isayama H, Nakai Y, Yoshikawa T, Ishigaki K, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Hayashi N, Koike K.

Pancreas. 2017 Jul;46(6):801-805. doi: 10.1097/MPA.0000000000000833.

PMID:
28609369
12.

Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.

Nakagawa H, Suzuki N, Hirata Y, Hikiba Y, Hayakawa Y, Kinoshita H, Ihara S, Uchino K, Nishikawa Y, Ijichi H, Otsuka M, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Tateishi K, Koike K.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):E3806-E3815. doi: 10.1073/pnas.1619416114. Epub 2017 Apr 24.

13.

Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion.

Ikenoue T, Terakado Y, Nakagawa H, Hikiba Y, Fujii T, Matsubara D, Noguchi R, Zhu C, Yamamoto K, Kudo Y, Asaoka Y, Yamaguchi K, Ijichi H, Tateishi K, Fukushima N, Maeda S, Koike K, Furukawa Y.

Sci Rep. 2017 Jan 3;7:39567. doi: 10.1038/srep39567. No abstract available.

14.

Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression.

Tanaka Y, Tateishi K, Nakatsuka T, Kudo Y, Takahashi R, Miyabayashi K, Yamamoto K, Asaoka Y, Ijichi H, Tateishi R, Shibahara J, Fukayama M, Ishizawa T, Hasegawa K, Kokudo N, Koike K.

Oncogenesis. 2016 Dec 12;5(12):e277. doi: 10.1038/oncsis.2016.76.

15.

Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1.

Kishikawa T, Otsuka M, Yoshikawa T, Ohno M, Ijichi H, Koike K.

Nat Commun. 2016 Sep 26;7:13006. doi: 10.1038/ncomms13006.

16.

No Survival Benefit from the Inhibition of Renin-Angiotensin System in Biliary Tract Cancer.

Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Takeda T, Umefune G, Saito T, Takagi K, Watanabe T, Hamada T, Uchino R, Mizuno S, Yamamoto K, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.

Anticancer Res. 2016 Sep;36(9):4965-70.

PMID:
27630357
17.

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.

Yamamoto K, Tateishi K, Kudo Y, Hoshikawa M, Tanaka M, Nakatsuka T, Fujiwara H, Miyabayashi K, Takahashi R, Tanaka Y, Ijichi H, Nakai Y, Isayama H, Morishita Y, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M, Koike K.

Oncotarget. 2016 Sep 20;7(38):61469-61484. doi: 10.18632/oncotarget.11129.

18.

TGF-β Signaling in Dendritic Cells Governs Colonic Homeostasis by Controlling Epithelial Differentiation and the Luminal Microbiota.

Ihara S, Hirata Y, Serizawa T, Suzuki N, Sakitani K, Kinoshita H, Hayakawa Y, Nakagawa H, Ijichi H, Tateishi K, Koike K.

J Immunol. 2016 Jun 1;196(11):4603-13. doi: 10.4049/jimmunol.1502548. Epub 2016 Apr 22.

19.

A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion.

Ikenoue T, Terakado Y, Nakagawa H, Hikiba Y, Fujii T, Matsubara D, Noguchi R, Zhu C, Yamamoto K, Kudo Y, Asaoka Y, Yamaguchi K, Ijichi H, Tateishi K, Fukushima N, Maeda S, Koike K, Furukawa Y.

Sci Rep. 2016 Apr 1;6:23899. doi: 10.1038/srep23899. Erratum in: Sci Rep. 2017 Jan 03;7:39567.

20.

A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.

Mohri D, Ijichi H, Miyabayashi K, Takahashi R, Kudo Y, Sasaki T, Asaoka Y, Tanaka Y, Ikenoue T, Tateishi K, Tada M, Isayama H, Koike K.

J Gastroenterol. 2016 Jul;51(7):711-21. doi: 10.1007/s00535-015-1145-1. Epub 2015 Nov 27.

PMID:
26614007
21.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Asaoka Y, Ijichi H, Koike K.

N Engl J Med. 2015 Nov 12;373(20):1979. doi: 10.1056/NEJMc1510353. No abstract available.

PMID:
26559583
22.

[IPMN and pancreatic cyst as high risk of pancreatic cancer].

Tada M, Takagi K, Kawakubo K, Hakuta R, Ishigaki K, Takeda T, Fujiwara H, Umefune G, Saito K, Saito T, Watanabe T, Akiyama D, Uchino R, Kishikawa T, Takahara N, Takahashi R, Yamamoto K, Hamada T, Mizuno S, Miyabayashi K, Mohri D, Matsubara S, Kogure H, Nakai Y, Yamamoto N, Sasaki T, Sasahira N, Hirano K, Ijichi H, Tateishi K, Isayama H, Koike K.

Nihon Shokakibyo Gakkai Zasshi. 2015 Aug;112(8):1474-8. doi: 10.11405/nisshoshi.112.1474. Japanese. No abstract available.

PMID:
26250126
23.

[Animal model of pancreatic cancer].

Ijichi H.

Nihon Rinsho. 2015 Mar;73 Suppl 3:31-6. Japanese. No abstract available.

PMID:
25856981
24.

Pancreatic cancer with malignant ascites: clinical features and outcomes.

Takahara N, Isayama H, Nakai Y, Sasaki T, Saito K, Hamada T, Mizuno S, Miyabayashi K, Mohri D, Kogure H, Matsubara S, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.

Pancreas. 2015 Apr;44(3):380-5. doi: 10.1097/MPA.0000000000000290.

PMID:
25636085
25.

The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients.

Nakai Y, Isayama H, Sasaki T, Takahara N, Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.

J Cancer Res Clin Oncol. 2015 May;141(5):933-9. doi: 10.1007/s00432-014-1873-2. Epub 2014 Nov 15.

PMID:
25398651
26.

Photoacoustic tomography of human hepatic malignancies using intraoperative indocyanine green fluorescence imaging.

Miyata A, Ishizawa T, Kamiya M, Shimizu A, Kaneko J, Ijichi H, Shibahara J, Fukayama M, Midorikawa Y, Urano Y, Kokudo N.

PLoS One. 2014 Nov 7;9(11):e112667. doi: 10.1371/journal.pone.0112667. eCollection 2014.

27.

Glasgow Prognostic Score (GPS) can be a useful indicator to determine prognosis of patients with colorectal carcinoma.

Nozoe T, Matono R, Ijichi H, Ohga T, Ezaki T.

Int Surg. 2014 Sep-Oct;99(5):512-7. doi: 10.9738/INTSURG-D-13-00118.1.

28.

Evaluation of graft stiffness using acoustic radiation force impulse imaging after living donor liver transplantation.

Ijichi H, Shirabe K, Matsumoto Y, Yoshizumi T, Ikegami T, Kayashima H, Morita K, Toshima T, Mano Y, Maehara Y.

Clin Transplant. 2014 Nov;28(11):1256-62. doi: 10.1111/ctr.12457. Epub 2014 Oct 15.

PMID:
25203425
29.

A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.

Nakai Y, Isayama H, Saito K, Sasaki T, Takahara N, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.

Cancer Chemother Pharmacol. 2014 Nov;74(5):911-5. doi: 10.1007/s00280-014-2563-0. Epub 2014 Aug 21.

PMID:
25143299
30.

[Development of basic research of pancreatic cancer: from genetically-engineered mouse models to bedside].

Ijichi H.

Nihon Shokakibyo Gakkai Zasshi. 2014 Aug;111(8):1561-9. Review. Japanese. No abstract available.

PMID:
25100345
31.

Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients.

Mizuno S, Nakai Y, Isayama H, Kawahata S, Saito T, Takagi K, Watanabe T, Uchino R, Hamada T, Miyabayashi K, Kogure H, Sasaki T, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Koike K.

Pancreas. 2014 Oct;43(7):1014-7. doi: 10.1097/MPA.0000000000000158.

PMID:
24979618
32.

Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα.

Yamamoto K, Tateishi K, Kudo Y, Sato T, Yamamoto S, Miyabayashi K, Matsusaka K, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Nakai Y, Isayama H, Ikenoue T, Kurokawa M, Fukayama M, Kokudo N, Omata M, Koike K.

Carcinogenesis. 2014 Nov;35(11):2404-14. doi: 10.1093/carcin/bgu136. Epub 2014 Jun 19.

PMID:
24947179
33.

Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.

Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, Yamaguchi H, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Kitayama J, Watanabe T, Koike K.

J Gastrointest Cancer. 2014 Sep;45(3):307-11. doi: 10.1007/s12029-014-9603-1.

PMID:
24676891
34.

Prognostic criteria in colorectal carcinoma constructed by the combination of tumor-related and host-related factors.

Nozoe T, Matono R, Ijichi H, Ohga T, Ezaki T.

Am J Surg. 2014 Jul;208(1):119-23. doi: 10.1016/j.amjsurg.2013.08.043. Epub 2014 Jan 3.

PMID:
24612685
35.

Recurrent hepatitis B following recurrence of hepatocellular carcinoma after living donor liver transplantation.

Ijichi H, Yoshizumi T, Ikegami T, Soejima Y, Ikeda T, Kawanaka H, Uchiyama H, Yamashita Y, Morita M, Oki E, Mimori K, Sugimachi K, Saeki H, Watanabe M, Shirabe K, Maehara Y.

Fukuoka Igaku Zasshi. 2013 Oct;104(10):376-82.

PMID:
24511669
36.

Loss of liver E-cadherin induces sclerosing cholangitis and promotes carcinogenesis.

Nakagawa H, Hikiba Y, Hirata Y, Font-Burgada J, Sakamoto K, Hayakawa Y, Taniguchi K, Umemura A, Kinoshita H, Sakitani K, Nishikawa Y, Hirano K, Ikenoue T, Ijichi H, Dhar D, Shibata W, Akanuma M, Koike K, Karin M, Maeda S.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1090-5. doi: 10.1073/pnas.1322731111. Epub 2014 Jan 6.

37.

A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer.

Nakai Y, Isayama H, Sasaki T, Takahara N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D, Kogure H, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1291-7.

PMID:
24121456
38.

A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.

Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.

Cancer Chemother Pharmacol. 2013 Nov;72(5):985-90. doi: 10.1007/s00280-013-2278-7. Epub 2013 Sep 1.

PMID:
23995699
39.

Disease-specific mortality among patients with intraductal papillary mucinous neoplasm of the pancreas.

Kawakubo K, Tada M, Isayama H, Sasahira N, Nakai Y, Takahara N, Uchino R, Hamada T, Miyabayashi K, Yamamoto K, Mizuno S, Mohri D, Kogure H, Sasaki T, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Koike K.

Clin Gastroenterol Hepatol. 2014 Mar;12(3):486-91. doi: 10.1016/j.cgh.2013.06.032. Epub 2013 Jul 25.

PMID:
23892276
40.

Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer.

Mizuno S, Nakai Y, Isayama H, Takahara N, Miyabayashi K, Yamamoto K, Kawakubo K, Mohri D, Kogure H, Sasaki T, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, Koike K.

Pancreatology. 2013 May-Jun;13(3):285-9. doi: 10.1016/j.pan.2013.03.013. Epub 2013 Apr 2.

PMID:
23719602
41.

Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.

Yamamoto S, Tateishi K, Kudo Y, Yamamoto K, Isagawa T, Nagae G, Nakatsuka T, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Aburatani H, Omata M, Koike K.

Carcinogenesis. 2013 Oct;34(10):2380-8. doi: 10.1093/carcin/bgt174. Epub 2013 May 22.

PMID:
23698634
42.

A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.

Nakai Y, Isayama H, Ijichi H, Sasaki T, Takahara N, Ito Y, Matsubara S, Uchino R, Yagioka H, Arizumi T, Hamada T, Miyabayashi K, Mizuno S, Yamamoto K, Kogure H, Yamamoto N, Hirano K, Sasahira N, Tateishi K, Tada M, Koike K.

Invest New Drugs. 2013 Oct;31(5):1294-9. doi: 10.1007/s10637-013-9972-5. Epub 2013 May 21.

PMID:
23690239
43.

Technical evolution of laparoscopic hepatic resection: a single institutional experience.

Soejima Y, Ikegami T, Ijichi H, Ikeda T, Shirabe K, Yoshizumi T, Uchiyama H, Yamashita Y, Harimoto N, Toshima T, Matsuura H, Okadome K, Maehara Y.

Fukuoka Igaku Zasshi. 2012 Nov;103(11):226-32.

PMID:
23397877
44.

Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.

Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, Ikenoue T, Tateishi K, Nakai Y, Isayama H, Morishita Y, Omata M, Moses HL, Koike K.

Cancer Res. 2013 Apr 1;73(7):2221-34. doi: 10.1158/0008-5472.CAN-12-1453. Epub 2013 Feb 1.

45.

Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer.

Takahashi R, Hirata Y, Sakitani K, Nakata W, Kinoshita H, Hayakawa Y, Nakagawa H, Sakamoto K, Hikiba Y, Ijichi H, Moses HL, Maeda S, Koike K.

Cancer Sci. 2013 Mar;104(3):337-44. doi: 10.1111/cas.12080. Epub 2013 Jan 24.

46.

Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas.

Kawakubo K, Tada M, Isayama H, Sasahira N, Nakai Y, Takahara N, Miyabayashi K, Yamamoto K, Mizuno S, Mohri D, Kogure H, Sasaki T, Yamamoto N, Tateishi R, Hirano K, Ijichi H, Tateishi K, Koike K.

Pancreas. 2013 May;42(4):687-91. doi: 10.1097/MPA.0b013e318270ea97.

PMID:
23211374
47.

Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma.

Ijichi H, Shirabe K, Taketomi A, Yoshizumi T, Ikegami T, Mano Y, Aishima S, Abe K, Honda H, Maehara Y.

Hepatol Res. 2013 May;43(5):481-7. doi: 10.1111/j.1872-034X.2012.01107.x. Epub 2012 Nov 12.

PMID:
23145869
48.

Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.

Takahara N, Nakai Y, Isayama H, Sasaki T, Satoh Y, Takai D, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tada M, Yatomi Y, Koike K.

Cancer Chemother Pharmacol. 2013 Jan;71(1):85-92. doi: 10.1007/s00280-012-1981-0. Epub 2012 Sep 29.

PMID:
23053265
49.

Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients.

Nakai Y, Isayama H, Sasaki T, Mizuno S, Sasahira N, Kogure H, Kawakubo K, Yamamoto N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.

Pancreas. 2013 Mar;42(2):202-8. doi: 10.1097/MPA.0b013e31825de678.

PMID:
23000889

Supplemental Content

Loading ...
Support Center